Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 July 2018 Photo Supplied
Five PhDs for Chemistry group at June 2018 graduation
Pictured here are the Department of Chemistry graduates and their promoters/ co-promoters. From the left are: Dr Alebel Belay, Dr Dumisani Kama, Dr Orbett Alexander, Dr Pennie Mokolokolo and Dr Pule Molokoane; back: Prof Andreas Roodt, Dr Marietjie Schutte-Smith, Dr Alice Brink and Dr Johan Venter. Prof Roodt was either promoter or co-promoter to four of the graduates, while Prof Deon Visser (promoter; not present) and Dr Alice Brink (co-promoter) supervised Dr Orbett Alexander.

What is the common factor among metal extraction from mineral reserves, the treatment of cancer, and nanomaterials in cellular phones? The answer is Chemistry. 

For the first time since the Department of Chemistry at the University of the Free State (UFS) was founded some 114 years ago, a single research group in Chemistry delivered five PhD students.  This was achieved in the division of Inorganic Chemistry at the 2018 Winter graduation ceremony by the group under leadership of Prof Andreas Roodt and senior colleagues, Drs Johan Venter, Alice Brink and Marietjie Schutte-Smith. Prof Deon Visser, a former group member, was promoter for one of the students. 

The five graduandi are Drs Alebel Belay, Dumisani Kama, Pennie Mokolokolo, Pule Molokoane and Orbett Alexander. Their research involved the use of special chemical groups which are attached to metals such as platinum, rhodium, niobium, technetium and rhenium to create compounds with special pre-selected properties. 

The combination of these special groups with the metals allow many different potential applications – all adding value. These include metal extraction from South Africa’s rich mineral reserves, the treatment of diseases such as cancer, the diagnosis of heart and brain damages, nanomaterials which are used in cellular phones, catalysts to produce cleaner petrol, special light devices which by themselves ‘glow in the dark’, and more. 

Three of the students completed part of their research in Switzerland.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept